Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | F12 | P00748 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15947640 | 0.83 | PLAU (0.54) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL29358794 | 0.79 | PLAU (0.50) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL251028 | 0.79 | PLAU (0.50) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL194554 | 0.79 | PLAU (0.50) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL2852412 | 0.79 | PLAU (0.50) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL7544045 | 0.79 | PLAU (0.50) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL27933452 | 0.76 | KDM4E (0.45) | MAPTLMNANPC1ALDH1A1RAB9A | |
| SCHEMBL15940603 | 0.75 | ADORA2A (0.54) | CYP2A6PLAUF12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL8116929 | 0.73 | ADORA2A (0.53) | CYP2A6PLAUF12NCF1NOS3 | |
| SCHEMBL2431412 | 0.73 | CYP2A6 (0.48) | CYP2A6PLAUF12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11005050-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| CN-106661031-B | Pyrrolopyrimidine compounds or its salt, pharmaceutical composition and application containing it | 大鹏药品工业株式会社 | 2019-07-23 | — | — | CN | disclosed |
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | TAIHO PHARMACETUICAL CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3395345-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-31 | — | — | EP | disclosed |
| EP-3102650-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9963456-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD (JP) | 2018-05-08 | — | — | US | disclosed |
| EP-3094638-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-11-08 | — | — | EP | disclosed |
| EP-3094638-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-11-08 | — | — | EP | disclosed |
| WO-2015117718-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015104045-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
| US-8723017-B2 | Dye sensitised solar cell | BASF SE (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2553698-A1 | DYE SENSITISED SOLAR CELL | BASF SE (DE) | 2013-02-06 | — | — | EP | disclosed |
| EP-2253031-B1 | DYE SENSITISED SOLAR CELL | BASF SE (DE) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011120908-A1 | DYE SENSITISED SOLAR CELL | BASF SE (DE) | 2011-10-06 | — | — | WO | disclosed |
| US-20110233477-A1 | Dye sensitised solar cell | BASF SE (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110061723-A1 | DYE SENSITISED SOLAR CELL | BASF SE (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2253031-A1 | DYE SENSITISED SOLAR CELL | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109499-A1 | DYE SENSITISED SOLAR CELL | BASF SE (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010158-A1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND | MCL1, TP53, DPYD | CYP2A6 4389/4885PLAU 1796/4885F12 4883/4885 |
| US-20110233477-A1 | Dye sensitised solar cell | SLC11A2, CRY1, MPO | CYP2A6 2926/4885PLAU 4354/4885F12 3702/4885 |
| US-10174040-B2 | Pyrrolopyrimidine compound or salt thereof and compositions containing the pyrrolopyrimidine compound or salt thereof | KRAS, DPYD, PSTPIP2 | CYP2A6 3788/4885PLAU 3050/4885F12 4463/4885 |
| US-20110061723-A1 | DYE SENSITISED SOLAR CELL | FTO, TET1, METTL14 | CYP2A6 3489/4885PLAU 4090/4885F12 4551/4885 |
| US-11005050-B2 | Metal complexes | SOD1, AP1M1, AP3M1 | CYP2A6 3927/4885PLAU 2801/4885F12 2850/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | CYP2A6 3788/4885PLAU 3050/4885F12 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.